CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the
appointment of Eugene Schneider, M.D., as executive vice
president and chief clinical development officer. In this role, Dr.
Schneider will oversee clinical development of novel antisense
medicines across all of Ionis' therapeutic franchises. He will
report to Richard S. Geary, Ph.D.,
Ionis' executive vice president and chief development officer, and
serve on the company's executive team.
Since joining Ionis in 2013, Dr. Schneider has played a key role
in more than 20 clinical trials conducted in the U.S. and globally.
He is an accomplished biopharmaceutical industry veteran with two
decades of experience leading global medical and scientific affairs
and the development and commercialization of medicines to treat a
range of disorders, including pediatric, rare and central nervous
system diseases.
"Dr. Schneider's proven track record overseeing successful
studies, assessing risk-benefit profiles of investigational
medicines and providing consistent clinical due diligence in safety
reporting will strengthen Ionis' industry leadership as we expand
our portfolio of wholly owned and partnered medicines and build our
commercial organization to maximize the value of our rich
pipeline," said Dr. Geary.
"I am excited to join Ionis' talented executive team and look
forward to continuing my work with them and all Ionis employees who
are deeply committed to delivering potentially transformative
medicines to patients who depend on us," said Dr. Schneider.
Before joining Ionis, Dr. Schneider was senior medical director,
clinical research and development at Synageva BioPharma, where he
developed a novel enzyme replacement therapy for Lysosomal Acid
Lipase Deficiency from its first-in-man study to
registration. Prior to Synageva, he was senior medical
director, medical and scientific affairs at Biovail Technologies
Ltd., where he was primarily responsible for the development and
commercialization of a diverse portfolio of medicines designed to
address patient needs related to central nervous system
disorders.
Dr. Schneider received his medical degree from the University of Medicine and Dentistry of New Jersey
and completed his training in pediatric and adolescent medicine at
Robert Wood Johnson University Hospital in New Brunswick, New Jersey.
ABOUT IONIS PHARMACEUTICALS, INC.
As the leader in RNA-targeted drug discovery and development, Ionis
has created an efficient, broadly applicable, drug discovery
platform called antisense technology that can treat diseases where
no other therapeutic approaches have proven effective. Our drug
discovery platform has served as a springboard for actionable
promise and realized hope for patients with unmet needs. We created
the first and only approved treatment for all patients, children
and adults with spinal muscular atrophy, as well as the world's
first RNA-targeted therapeutic approved for the treatment of
polyneuropathy in adults with hereditary transthyretin amyloidosis.
Our sights are set on all the patients we have yet to reach with a
pipeline of more than 40 novel medicines designed to potentially
treat a broad range of disease, including neurological,
cardio-renal, metabolic, infectious, and pulmonary diseases.
To learn more about Ionis
visit www.ionispharma.com and follow us on twitter
@ionispharma.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ionis-appoints-eugene-schneider-md-as-executive-vice-president-and-chief-clinical-development-officer-301203128.html
SOURCE Ionis Pharmaceuticals, Inc.